Adnan Butt
Stock Analyst at Guggenheim
(n/a)
# 4,541
Out of 4,900 analysts
8
Total ratings
n/a
Success rate
-31.56%
Average return
Main Sectors:
Stocks Rated by Adnan Butt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgrades: Buy | n/a | $127.50 | - | 3 | Oct 23, 2019 | |
| ITRM Iterum Therapeutics | Initiates: Outperform | $315 | $0.98 | +32,042.86% | 1 | Jun 19, 2018 | |
| SCYX SCYNEXIS | Initiates: Buy | $60 | $0.76 | +7,794.74% | 1 | Oct 24, 2017 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $12 | $11.09 | +8.21% | 1 | Oct 24, 2017 | |
| CRIS Curis | Initiates: Buy | $700 | $1.82 | +38,361.54% | 1 | Oct 24, 2017 | |
| REGN Regeneron Pharmaceuticals | Initiates: Sector Perform | $475 | $547.96 | -13.31% | 1 | Sep 15, 2017 |
Biogen
Oct 23, 2019
Upgrades: Buy
Price Target: n/a
Current: $127.50
Upside: -
Iterum Therapeutics
Jun 19, 2018
Initiates: Outperform
Price Target: $315
Current: $0.98
Upside: +32,042.86%
SCYNEXIS
Oct 24, 2017
Initiates: Buy
Price Target: $60
Current: $0.76
Upside: +7,794.74%
Ocular Therapeutix
Oct 24, 2017
Initiates: Buy
Price Target: $12
Current: $11.09
Upside: +8.21%
Curis
Oct 24, 2017
Initiates: Buy
Price Target: $700
Current: $1.82
Upside: +38,361.54%
Regeneron Pharmaceuticals
Sep 15, 2017
Initiates: Sector Perform
Price Target: $475
Current: $547.96
Upside: -13.31%